Jan Beumer — Patent Portfolio

Verdict The Jan Beumer pharmaceutical company portfolio is moderately strong, with a significant cliff year in 2026 and no revenue at risk in the next 5 years.

Portfolio overview The company's portfolio consists of a total of 1 drug with 36 active US patents, resulting in an average vulnerability score of 69. Out of these patents, 3 are considered ironclad, while 21 are vulnerable. Notably, the company does not have any biologics in its portfolio.

Cliff calendar In 2026, 1 drug will lose exclusivity, including nilotinib-hydrochloride. This marks a significant cliff year for the company, with a substantial loss of revenue expected.

Most exposed drugs The top drug facing near-term loss of exclusivity is nilotinib-hydrochloride, with an earliest active patent expiry date of 2026-07-18 and an average vulnerability score of 69. Unfortunately, the annual revenue for this drug is not available.

Biologic exclusivity The company does not have any biologics in its portfolio, meaning there are no biologics with BPCIA 12-year reference product exclusivity.

Strategic implications With no revenue at risk in the next 5 years, the company has a relatively stable portfolio. However, the loss of exclusivity for nilotinib-hydrochloride in 2026 will require strategic lifecycle management decisions, such as subQ switches, label extensions, or combination filings, to maintain revenue and competitiveness.